Humana Inc. (NYSE:HUM) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday, October 17th.
According to Zacks, “Humana is well poised to grow on its strong government business. Its top-line has been witnessing an uptrend from past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value. Humana’s sound balance sheet and disciplined capital management remains a positive. Following its strong second-quarter 2017 results, it raised its 2017 adjusted EPS guidance. The company has also seen the Zacks Consensus Estimate for the current year earnings being revised upward in last 30 days. Although the shares have performed in line with the industry in a year's time, its strong fundamentals are likely to help the stock in gaining momentum going forward. However, the company's individual commercial business has remained a drag over past few years. The company will release third quarter results on Nov 8, 2017.”
Other analysts also recently issued research reports about the stock. UBS AG reaffirmed a “neutral” rating and set a $237.00 price target (up previously from $205.00) on shares of Humana in a report on Wednesday, June 28th. BidaskClub cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Piper Jaffray Companies reiterated a “buy” rating and issued a $246.00 price objective on shares of Humana in a research note on Friday, July 14th. Jefferies Group LLC restated a “hold” rating and set a $257.00 target price on shares of Humana in a research note on Friday, August 4th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Humana in a research note on Friday, June 23rd. Twelve equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $253.90.
Humana (NYSE:HUM) traded up 3.68% on Tuesday, reaching $260.77. 1,161,050 shares of the company traded hands. Humana has a 52-week low of $165.03 and a 52-week high of $264.56. The stock has a 50-day moving average of $245.04 and a 200 day moving average of $237.59. The company has a market capitalization of $37.69 billion, a PE ratio of 21.45 and a beta of 0.86.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The company had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. During the same period in the prior year, the firm posted $2.30 EPS. On average, equities analysts forecast that Humana will post $11.57 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/humana-inc-hum-lowered-to-hold-at-zacks-investment-research.html.
In other news, CEO Bruce D. Broussard sold 12,000 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the sale, the chief executive officer now owns 80,086 shares in the company, valued at $20,172,061.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP M Todoroff Christopher sold 22,935 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $252.52, for a total value of $5,791,546.20. Following the sale, the vice president now owns 24,001 shares in the company, valued at approximately $6,060,732.52. The disclosure for this sale can be found here. Insiders have sold 55,595 shares of company stock worth $14,133,706 in the last 90 days. Insiders own 0.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Crossmark Global Holdings Inc. purchased a new stake in Humana in the third quarter valued at approximately $4,212,000. Raymond James Financial Services Advisors Inc. boosted its position in Humana by 68.0% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 4,724 shares of the insurance provider’s stock valued at $1,151,000 after buying an additional 1,912 shares during the last quarter. Pictet Asset Management Ltd. boosted its position in Humana by 6.1% in the third quarter. Pictet Asset Management Ltd. now owns 178,098 shares of the insurance provider’s stock valued at $43,390,000 after buying an additional 10,276 shares during the last quarter. Highstreet Asset Management Inc. boosted its position in Humana by 106.7% in the third quarter. Highstreet Asset Management Inc. now owns 6,014 shares of the insurance provider’s stock valued at $1,465,000 after buying an additional 3,104 shares during the last quarter. Finally, Aperio Group LLC boosted its position in Humana by 24.1% in the third quarter. Aperio Group LLC now owns 132,217 shares of the insurance provider’s stock valued at $32,212,000 after buying an additional 25,646 shares during the last quarter. Hedge funds and other institutional investors own 95.50% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Get a free copy of the Zacks research report on Humana (HUM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.